Interim OS analysis of a phase 3 RCT (874 patients) in ER+/HER2- advanced breast cancer: in ESR1m, median OS 34.5 months with imlunestrant vs 23.1 with standard care (HR 0.60), but the significance boundary was not reached.
RCTn = 874
Jhaveri et al. Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial